Curevo Vaccine https://validator.w3.org/feed/docs/rss2.html Home Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week About Us Careers Curevo Presents Positive Shingles Vaccine Outcomes Data Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer Amezosvatein for Chickenpox Amezosvatein for Shingles Management Team Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine Curevo Enrolls First Participants in Phase 2 Extension Trial Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference  Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix  <strong>Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines</strong> Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles Curevo Vaccine Receives 2022 Best of Bothell Award GC Pharma to Establish Curevo Curevo Presents at IHW 2018 in Vancouver Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101 Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101 Curevo Presenting at World Vaccine Conference Congress (Washington) Sept 28 – Oct 1 A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines $60 Million Funding Supports Shingles Vaccine Candidate Curevo Vaccine #JPM26 Meeting Space Information Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot Terms of Use SAHPRA Approval Press Announcement 2021 Cookie Policy Contact Us Privacy Policy News Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer